Compare LFVN & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFVN | ECOR |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.0M | 50.0M |
| IPO Year | 1996 | 2018 |
| Metric | LFVN | ECOR |
|---|---|---|
| Price | $5.18 | $6.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | ★ 165.1K | 49.2K |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | ★ 226.09 | 53.51 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $203,204,000.00 | $25,182,000.00 |
| Revenue This Year | N/A | $28.92 |
| Revenue Next Year | N/A | $32.50 |
| P/E Ratio | $25.68 | ★ N/A |
| Revenue Growth | 1.86 | ★ 57.09 |
| 52 Week Low | $3.90 | $4.16 |
| 52 Week High | $17.64 | $13.81 |
| Indicator | LFVN | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 52.51 | 46.83 |
| Support Level | $4.32 | $4.64 |
| Resistance Level | $5.32 | $6.61 |
| Average True Range (ATR) | 0.31 | 0.70 |
| MACD | 0.09 | -0.06 |
| Stochastic Oscillator | 83.17 | 25.73 |
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.